These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36305272)

  • 1. Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings.
    Dong J; Varbanov M; Philippot S; Vreken F; Zeng WB; Blay V
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):24-35. PubMed ID: 36305272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
    Fischer A; Sellner M; Neranjan S; Smieško M; Lill MA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an
    Ferraz WR; Gomes RA; S Novaes AL; Goulart Trossini GH
    Future Med Chem; 2020 Oct; 12(20):1815-1828. PubMed ID: 32787684
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
    Deodato D; Asad N; Dore TM
    Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery.
    Xu L; Chen R; Liu J; Patterson TA; Hong H
    Drug Discov Today; 2023 Oct; 28(10):103727. PubMed ID: 37516343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 16. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
    Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
    J Chem Theory Comput; 2020 Nov; 16(11):7160-7172. PubMed ID: 33090785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel inhibitors of SARS-CoV-2 main protease.
    Zheng L; Chen Y; Bao J; He L; Dong S; Qi Y; Zhang JZH
    J Biomol Struct Dyn; 2022; 40(23):12526-12534. PubMed ID: 34472424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2.
    Kodchakorn K; Poovorawan Y; Suwannakarn K; Kongtawelert P
    J Mol Graph Model; 2020 Dec; 101():107717. PubMed ID: 32861974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
    Elkaeed EB; Eissa IH; Elkady H; Abdelalim A; Alqaisi AM; Alsfouk AA; Elwan A; Metwaly AM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.